Education
About Us
Working with TipRanks
Follow Us
Sarepta Therapeutics (SRPT)
NASDAQ:SRPT
SRPT Analyst Ratings
Strong Buy
18 Buy
4 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
SRPT Stock 12 Month Forecast
Average Price Target
$151.58
▲(181.02% Upside)
| Highest Price Target$209.00 | Average Price Target$151.58 | Lowest Price Target$70.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Bank of America Securities
Reiterated
04/17/25
TD Cowen
Reiterated
04/16/25
H.C. Wainwright
Reiterated
04/16/25
Morgan Stanley
Reiterated
04/15/25
Wells Fargo
Reiterated
04/15/25
Guggenheim
Reiterated
04/10/25
J.P. Morgan
Reiterated
04/08/25
Oppenheimer
Reiterated
04/07/25
Scotiabank
Reiterated
04/07/25
Barclays
Reiterated
04/04/25
Deutsche Bank
$99→$70
Hold
29.77%
Upside
Reiterated
04/03/25
Sarepta price target lowered to $70 from $99 at Deutsche BankSarepta price target lowered to $70 from $99 at Deutsche Bank
RBC Capital
$87
Hold
61.29%
Upside
Reiterated
04/03/25
Sarepta Therapeutics (SRPT) Gets a Hold from RBC Capital
Needham
$202→$183
Buy
239.27%
Upside
Reiterated
04/03/25
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (NASDAQ: SRPT) and AC Immune SA (NASDAQ: ACIU)
Leerink Partners
―
Buy
―
Reiterated
04/02/25
Sarepta Therapeutics: Undervalued Stock with Strong US Market Potential Despite EMA HoldWe also know that this patient was on the older side (16-years old) and likely heavier (versus younger patients), which requires a higher dose. As we previously outlined (here), we acknowledge that such severe side effects associated with mortality can certainly be alarming and cause the community to question the risk/benefit of treating older patients. However, we believe that the very low overall incidence, which we estimate at <0.125% based on aggregate exposure to date, is encouraging (>800 patients dosed in clinical trials or as a prescribed therapy). Approvability in the EU has long been a question and as such, we continue to assume a 60% probability-of-success/PoS in the EU and RoW. Moreover, considering the partnership with Roche, ex- US sales are not a major value driver for our model, nor are they a core focus for investors.
BMO Capital
$200
Buy
270.78%
Upside
Reiterated
04/02/25
Positive Outlook for Sarepta Therapeutics Amid Elevidys Trial Hold and Strong Market Position
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Bank of America Securities
Reiterated
04/17/25
TD Cowen
Reiterated
04/16/25
H.C. Wainwright
Reiterated
04/16/25
Morgan Stanley
Reiterated
04/15/25
Wells Fargo
Reiterated
04/15/25
Guggenheim
Reiterated
04/10/25
J.P. Morgan
Reiterated
04/08/25
Oppenheimer
Reiterated
04/07/25
Scotiabank
Reiterated
04/07/25
Barclays
Reiterated
04/04/25
Deutsche Bank
$99→$70
Hold
29.77%
Upside
Reiterated
04/03/25
Sarepta price target lowered to $70 from $99 at Deutsche BankSarepta price target lowered to $70 from $99 at Deutsche Bank
RBC Capital
$87
Hold
61.29%
Upside
Reiterated
04/03/25
Sarepta Therapeutics (SRPT) Gets a Hold from RBC Capital
Needham
$202→$183
Buy
239.27%
Upside
Reiterated
04/03/25
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (NASDAQ: SRPT) and AC Immune SA (NASDAQ: ACIU)
Leerink Partners
―
Buy
―
Reiterated
04/02/25
Sarepta Therapeutics: Undervalued Stock with Strong US Market Potential Despite EMA HoldWe also know that this patient was on the older side (16-years old) and likely heavier (versus younger patients), which requires a higher dose. As we previously outlined (here), we acknowledge that such severe side effects associated with mortality can certainly be alarming and cause the community to question the risk/benefit of treating older patients. However, we believe that the very low overall incidence, which we estimate at <0.125% based on aggregate exposure to date, is encouraging (>800 patients dosed in clinical trials or as a prescribed therapy). Approvability in the EU has long been a question and as such, we continue to assume a 60% probability-of-success/PoS in the EU and RoW. Moreover, considering the partnership with Roche, ex- US sales are not a major value driver for our model, nor are they a core focus for investors.
BMO Capital
$200
Buy
270.78%
Upside
Reiterated
04/02/25
Positive Outlook for Sarepta Therapeutics Amid Elevidys Trial Hold and Strong Market Position
Best Analysts Covering Sarepta Therapeutics
Which Analyst Should I Follow If I Want to Buy SRPT and Sell After:
1 Month
xxx
Success Rate
29/45 ratings generated profit
Average Return
+3.02%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 64.44% of your transactions generating a profit, with an average return of +3.02% per trade.
3 Months
xxx
Success Rate
22/38 ratings generated profit
Average Return
+7.31%
reiterated a xxx
rating 8 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 57.89% of your transactions generating a profit, with an average return of +7.31% per trade.
1 Year
Success Rate
29/45 ratings generated profit
Average Return
+10.30%
reiterated a buy rating 5 months ago
Copying Brian Skorney's trades and holding each position for 1 Year would result in 64.44% of your transactions generating a profit, with an average return of +10.30% per trade.
2 Years
xxx
Success Rate
19/45 ratings generated profit
Average Return
-5.26%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 42.22% of your transactions generating a profit, with an average return of -5.26% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
SRPT Analyst Recommendation Trends
Rating
Dec 24
Jan 25
Feb 25
Mar 25
Apr 25
Strong Buy
31
36
31
45
44
Buy
17
23
12
15
7
Hold
0
0
1
5
10
Sell
3
5
6
5
3
Strong Sell
0
0
0
0
0
total
51
64
50
70
64
Each month's total comprises the sum of three months' worth of ratings.
SRPT Financial Forecast
SRPT Stock Forecast FAQ
What is SRPT’s average 12-month price target, according to analysts?
Based on analyst ratings, Sarepta Therapeutics’s 12-month average price target is $151.58.
What is SRPT’s upside potential, based on the analysts’ average price target?
Sarepta Therapeutics has 181.02% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is SRPT a Buy, Sell or Hold?
Sarepta Therapeutics has a consensus rating of Strong Buy which is based on 18 buy ratings, 4 hold ratings and 0 sell ratings.
What is Sarepta Therapeutics’s price target?
The average price target for Sarepta Therapeutics is $151.58. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $209.00 ,the lowest forecast is $70.00. The average price target represents 181.02% Increase from the current price of $53.94.
The highest analyst price target is $209.00 ,the lowest forecast is $70.00. The average price target represents 181.02% Increase from the current price of $53.94.
What do analysts say about Sarepta Therapeutics?
Sarepta Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 22 Wall Streets Analysts.
How can I buy shares of SRPT?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.